Parameters analysis of FitzHugh-Nagumo model for a reliable simulation.

Derived from the pioneer ionic Hodgkin-Huxley model and due to its simplicity and richness from a point view of nonlinear dynamics, the FitzHugh-Nagumo model (FHN) is one of the most successful simplified neuron / cardiac cell model. There exist many variations of the original FHN model. Though these FHN type models help to enrich the dynamics of the FHN model, the parameters used in these models are often in biased conditions. The related results would be questionable. So, in this study, the aim is to find the parameter thresholds for one of the commonly used FHN model in order to provide a better simulation environment. The results showed at first that inappropriate time step and integration tolerance in numerical solution of FHN model can give some biased results which would make some publications questionable. Then the thresholds of parameters α, γ and ε are presented. α controls the global dynamics of FHN. α > 0, the cell is in refractory mode; α <; 0, the cell is excitable. ε controls the main morphology of the action potential generated and has a relation with the period (P = 3.065 × αα,γ(-0.8275)+ 4.397). To show oscillations of relaxation with FHN, ε should be smaller than 0.0085. 7 influences barely action potential, it showed linear relationship with the period and duration of action potential. Even though α <; 0.1, ε <; 0.0085, there is no definite threshold for γ, smaller values are recommended.

European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).

Germ cell tumour is the most frequent malignant tumour type in young men with a 100% rise in the incidence every 20 years. Despite this, the high sensitivity of germ cell tumours to platinum-based chemotherapy, together with radiation and surgical measures, leads to the high cure rate of > or = 99% in early stages and 90%, 75-80% and 50% in advanced disease with 'good', 'intermediate' and 'poor' prognostic criteria (IGCCCG classification), respectively. The high cure rate in patients with limited metastatic disease allows the reduction of overall treatment load, and therefore less acute and long-term toxicity, e.g. organ sparing surgery for specific cases, reduced dose and treatment volume of irradiation or substitution of node dissection by surveillance or adjuvant chemotherapy according to the presence or absence of vascular invasion. Thus, different treatment options according to prognostic factors including histology, stage and patient factors and possibilities of the treating centre as well may be used to define the treatment strategy which is definitively chosen for an individual patient. However, this strategy of reduction of treatment load as well as the treatment itself require very high expertise of the treating physician with careful management and follow-up and thorough cooperation by the patient as well to maintain the high rate for cure. Treatment decisions must be based on the available evidence which has been the basis for this consensus guideline delivering a clear proposal for diagnostic and treatment measures in each stage of gonadal and extragonadal germ cell tumour and individual clinical situations. Since this guideline is based on the highest evidence level available today, a deviation from these proposals should be a rare and justified exception.